Acute Cholecystitis Management (TG18 2018)
Acute Cholecystitis Management (TG18 2018): Suspected Acute Cholecystitis → TG18 Diagnostic Criteria Met? → Determine TG18 Severity Grade → Grade I (Mil...
Interactive Decision Tree
Algorithm Steps
- ▶Start
Suspected Acute Cholecystitis
Patient with RUQ pain, fever, and/or Murphy sign. Consider if: local signs (RUQ pain/tenderness, Murphy sign) + systemic signs (fever, elevated CRP, leukocytosis) + imaging findings
- ◆Decision
TG18 Diagnostic Criteria Met?
A: Local signs (Murphy sign, RUQ mass/pain/tenderness) + B: Systemic inflammation (fever >38°C, CRP elevated, WBC >10,000/mm³) + C: Imaging findings (US/CT showing gallbladder wall thickening >4mm, pericholecystic fluid, gallstones). Definite: A + B + C. Suspected: A + B
- ◆Decision
Determine TG18 Severity Grade
Grade I (Mild): No organ dysfunction, mild inflammatory changes. Grade II (Moderate): WBC >18,000/mm³ OR palpable RUQ mass OR duration >72h OR marked local inflammation (gangrenous, pericholecystic abscess, hepatic abscess, biliary peritonitis, emphysematous). Grade III (Severe): Organ dysfunction in any system
- ●Action
Grade I (Mild)
No organ dysfunction and mild disease. Local inflammation only.
- ◆Decision
Surgical Risk Assessment
Assess Charlson Comorbidity Index (CCI) and ASA Physical Status (ASA-PS). Early Lap-C if CCI ≤5 AND ASA-PS ≤2
- ●Action
Early Laparoscopic Cholecystectomy
Perform Lap-C as soon as possible, ideally within 72 hours of symptom onset. Early surgery reduces conversion rates, complications, and hospital stay.
- ●Action
Antibiotic Selection (TG18)
Community-acquired Grade I-II: Cefazolin or ceftriaxone. Grade II with risk factors or Grade III: Piperacillin-tazobactam, carbapenem, or cephalosporin + metronidazole. Healthcare-associated: Add vancomycin for MRSA coverage. Duration: Until cholecystectomy for uncomplicated; 4-7 days post source control for complicated.
- ✓Outcome
Cholecystectomy Completed
Definitive surgical management achieved. Routine postoperative care. Pathology review for gangrenous/malignancy.
- ✓Outcome
Drainage + Delayed Surgery
Patient stabilized with drainage. Plan interval cholecystectomy in 6-8 weeks. Follow-up imaging to confirm resolution.
- ●Action
Conservative Management
IV fluids, bowel rest, IV antibiotics. Consider percutaneous gallbladder drainage if no improvement in 24-48h. Plan delayed Lap-C after inflammation resolves (6-8 weeks).
- ●Action
Grade II (Moderate)
Marked local inflammation: WBC >18,000/mm³, palpable mass, duration >72h, or local complications (gangrenous, abscess)
- ◆Decision
Advanced Laparoscopic Skills Available?
Assess surgical expertise and patient factors. Experienced laparoscopic surgeon at advanced center? Patient CCI and ASA-PS acceptable for surgery?
- ●Action
Early Lap-C by Expert Surgeon
Perform Lap-C with experienced surgeon. Higher conversion risk but acceptable. Consider subtotal cholecystectomy if severe inflammation.
- ●Action
Early Biliary Drainage
Percutaneous transhepatic gallbladder drainage (PTGBD) or endoscopic approach. Stabilize patient. Plan delayed cholecystectomy once inflammation resolves.
- ●Action
Grade III (Severe)
Organ dysfunction present: CV (hypotension requiring vasopressors), Neurological (decreased consciousness), Respiratory (PaO2/FiO2 <300), Renal (oliguria, Cr >2.0), Hepatic (PT-INR >1.5), Hematologic (Plt <100,000)
- ●Action
Intensive Organ Support
ICU admission. Aggressive resuscitation: IV fluids, vasopressors if needed, respiratory support. Initiate broad-spectrum antibiotics immediately.
- ●Action
Urgent Biliary Drainage
PTGBD is first-line for source control. Endoscopic drainage as alternative. NOT early cholecystectomy - too high risk. Cholecystectomy only after full recovery and optimization.
- ⚠Warning
⚠️ Watch for Gangrenous Cholecystitis
Signs: persistent fever despite antibiotics, high WBC, gas in gallbladder wall (emphysematous), perforation on imaging. Requires urgent surgery or drainage even if Grade III. Mortality significantly increased if delayed.
Guideline Source
Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not address acalculous cholecystitis in detail
- Pediatric patients require specialized consideration
- Pregnancy requires modified approach
- Local surgical expertise influences Grade III management decisions
- Institutional protocols may vary for biliary drainage techniques
Contraindicated Populations
Applicable Regions
Global: TG18 is the international standard for acute cholecystitis management
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
Caprini VTE Risk Score
Venous thromboembolism risk assessment for surgical patients
Compare
AttendMe.ai vs BMJ Best Practice
See how this pathway workflow compares against BMJ Best Practice.
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Related Resources
Frequently Asked Questions
What is the Acute Cholecystitis Management (TG18 2018)?
The Acute Cholecystitis Management (TG18 2018) is a emergency clinical algorithm for General Surgery. It provides a structured decision tree to guide clinical decision-making, based on Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis.
What guideline is the Acute Cholecystitis Management (TG18 2018) based on?
This algorithm is based on Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis (DOI: 10.1002/jhbp.516).
What are the limitations of the Acute Cholecystitis Management (TG18 2018)?
Known limitations include: Does not address acalculous cholecystitis in detail; Pediatric patients require specialized consideration; Pregnancy requires modified approach; Local surgical expertise influences Grade III management decisions; Institutional protocols may vary for biliary drainage techniques. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Acute Cholecystitis Management (TG18 2018) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free